Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recessive oncogenes

R Bookstein1, D C Allred

  • 1Institute of Biotechnology, University of Texas Health Science Center, San Antonio.

Cancer
|February 1, 1993
PubMed
Summary
This summary is machine-generated.

Tumor suppressor gene mutations, like those in retinoblastoma (RB) and p53, are crucial in cancer development. These genetic changes, including in prostate cancer, drive tumor growth and offer therapeutic targets.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis.

Cell death and differentiation·2013
Same author

Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.

Endocrine-related cancer·2005
Same author

Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.

Breast cancer research and treatment·2005
Same author

Introduction: models of premalignant breast disease.

Journal of mammary gland biology and neoplasia·2004
Same author

Biological features of premalignant disease in the human breast.

Journal of mammary gland biology and neoplasia·2004
Same author

Developmental and hormonal signals dramatically alter the localization and abundance of insulin receptor substrate proteins in the mammary gland.

Endocrinology·2003

Area of Science:

  • Molecular Oncology
  • Cancer Genetics
  • Tumorigenesis

Background:

  • Tumor-suppressor genes (antioncogenes) inactivate oncogenes, preventing cancer.
  • Oncogenes arise from proto-oncogenes through activating mutations.
  • Most human cancers involve mutations in multiple suppressor genes and/or oncogenes.

Purpose of the Study:

  • To investigate the role of tumor-suppressor genes, specifically retinoblastoma (RB) and p53, in prostate carcinoma.
  • To identify potential novel suppressor genes involved in prostate cancer development through allelic loss analysis.

Main Methods:

  • Analysis of mutations in well-characterized tumor-suppressor genes (RB, p53) in prostate cancer.
  • Assessment of neoplastic properties upon reintroduction of normal RB or p53 alleles.

Related Experiment Videos

  • Examination of allelic losses on specific chromosome arms (8p, 10p/q, 16q) in prostate cancer cells.

    • Main Results:

    • Mutations in RB and p53 genes are found in a subset of prostate carcinomas.
    • Introduction of wild-type RB or p53 suppresses neoplastic behavior in mutated prostate cancer cells.
    • Frequent allelic losses on chromosomes 8p, 10p/q, and 16q suggest the presence of novel prostate cancer suppressor genes.

    Conclusions:

    • RB and p53 gene mutations contribute to the genesis or progression of some prostate cancers.
    • Inactivation of tumor suppressor genes is a common mechanism in human oncogenesis, with varying mutation rates across cancer types.
    • Further research is needed to determine if RB/p53-mutated prostate cancers have distinct biological or prognostic profiles.